616 related articles for article (PubMed ID: 19283918)
21. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
22. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
23. Interaction between goserelin and tamoxifen in a prospective randomised clinical trial of adjuvant endocrine therapy in premenopausal breast cancer.
Sverrisdottir A; Johansson H; Johansson U; Bergh J; Rotstein S; Rutqvist L; Fornander T
Breast Cancer Res Treat; 2011 Aug; 128(3):755-63. PubMed ID: 21625929
[TBL] [Abstract][Full Text] [Related]
24. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
25. [The use of GnRH analogues in early and advanced breast carcinomas].
Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
[TBL] [Abstract][Full Text] [Related]
26. Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer.
Ejlertsen B; Mouridsen HT; Jensen MB; Bengtsson NO; Bergh J; Cold S; Edlund P; Ewertz M; de Graaf PW; Kamby C; Nielsen DL
J Clin Oncol; 2006 Nov; 24(31):4956-62. PubMed ID: 17075113
[TBL] [Abstract][Full Text] [Related]
27. Expanding role of ovarian suppression/ablation in premenopausal ER-positive breast cancer: issues and opportunities.
Schem C; Jonat W
Oncology (Williston Park); 2009 Jan; 23(1):44, 47. PubMed ID: 19283921
[No Abstract] [Full Text] [Related]
28. Ovarian ablation as adjuvant therapy for premenopausal women with breast cancer--another step forward.
Pater JL; Parulekar WR
J Natl Cancer Inst; 2003 Dec; 95(24):1811-2. PubMed ID: 14679143
[No Abstract] [Full Text] [Related]
29. Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Cianfrocca M; Wolff AC
Oncology (Williston Park); 2007 Jan; 21(1):63-9; discussion 69, 72, 75 passim. PubMed ID: 17313157
[TBL] [Abstract][Full Text] [Related]
30. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):516-25. PubMed ID: 17405996
[TBL] [Abstract][Full Text] [Related]
31. Ovarian ablation as adjuvant therapy for early-stage breast cancer.
Pritchard KI
Cancer Treat Res; 1998; 94():158-80. PubMed ID: 9587687
[No Abstract] [Full Text] [Related]
32. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
Bao T; Davidson NE
Breast Cancer Res; 2007; 9(6):115. PubMed ID: 18190722
[TBL] [Abstract][Full Text] [Related]
33. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
von Minckwitz G; Graf E; Geberth M; Eiermann W; Jonat W; Conrad B; Brunnert K; Gerber B; Vescia S; Wollert J; Kaufmann M
Eur J Cancer; 2006 Aug; 42(12):1780-8. PubMed ID: 16765589
[TBL] [Abstract][Full Text] [Related]
34. Quality of life in goserelin-treated versus cyclophosphamide + methotrexate + fluorouracil-treated premenopausal and perimenopausal patients with node-positive, early breast cancer: the Zoladex Early Breast Cancer Research Association Trialists Group.
de Haes H; Olschewski M; Kaufmann M; Schumacher M; Jonat W; Sauerbrei W;
J Clin Oncol; 2003 Dec; 21(24):4510-6. PubMed ID: 14610048
[TBL] [Abstract][Full Text] [Related]
35. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
Gnant M; Mlineritsch B; Schippinger W; Luschin-Ebengreuth G; Pöstlberger S; Menzel C; Jakesz R; Seifert M; Hubalek M; Bjelic-Radisic V; Samonigg H; Tausch C; Eidtmann H; Steger G; Kwasny W; Dubsky P; Fridrik M; Fitzal F; Stierer M; Rücklinger E; Greil R; ; Marth C
N Engl J Med; 2009 Feb; 360(7):679-91. PubMed ID: 19213681
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer: adjuvant modalities.
Sakr BJ; Dizon DS
Clin Obstet Gynecol; 2011 Mar; 54(1):150-6. PubMed ID: 21278514
[TBL] [Abstract][Full Text] [Related]
37. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
Lancet; 2005 May 14-20; 365(9472):1687-717. PubMed ID: 15894097
[TBL] [Abstract][Full Text] [Related]
38. Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference.
Rabaglio M; Aebi S; Castiglione-Gertsch M
Lancet Oncol; 2007 Oct; 8(10):940-9. PubMed ID: 17913663
[TBL] [Abstract][Full Text] [Related]
39. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
[TBL] [Abstract][Full Text] [Related]
40. Same gain, less pain: potential patient preferences for adjuvant treatment in premenopausal women with early breast cancer.
Fallowfield L; McGurk R; Dixon M
Eur J Cancer; 2004 Nov; 40(16):2403-10. PubMed ID: 15519512
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
